Format

Send to

Choose Destination
Blood Cells Mol Dis. 2016 Jul;59:58-62. doi: 10.1016/j.bcmd.2016.04.007. Epub 2016 Apr 19.

EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.

Author information

1
Department of paediatric Hematology and Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
2
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
3
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
4
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address: 602538200@qq.com.

Abstract

Imatinib (IM) resistant Chronic Myeloid Leukemia (CML) is an important issue to be addressed while treating CML patients. The present study analyzes the role of EphB4-VAV1 signaling in IM-resistant CML. EphB4 and VAV1 were overexpressed in IM-resistant CML patients and K562-R cell line (K562-R). Then, we established stable under-expressing EphB4 cell line K562-R-EphB4-sh. VAV1 was down-regulated in K562-R-EphB4-sh cells. K562-R-EphB4-sh cells gained re-sensitivity to IM and K562-R cells showed mild IM resistance. However, EphB4 was no changed when the VAV1 was down-regulated. EphB4 and VAV1 were overexpressed in IM-resistant CML, VAV1might be the downstream moleculars of EphB4. These results suggest a potential role of EphB4-VAV1 signaling as therapeutic target of IM-resistant CML.

KEYWORDS:

Chronic myeloid leukemia; EphB4; Imatinib resistance; VAV1

PMID:
27282569
DOI:
10.1016/j.bcmd.2016.04.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center